QuantumScape Co. (NYSE:QS – Get Rating) was the target of unusually large options trading on Thursday. Traders purchased 32,286 call options on the stock. This represents an increase of 51% compared to the typical daily volume of 21,379 call options.
QuantumScape Price Performance
Shares of NYSE QS opened at $11.31 on Friday. The business’s 50 day moving average price is $11.12 and its two-hundred day moving average price is $12.93. The company has a market cap of $4.89 billion, a PE ratio of -15.71 and a beta of 6.57. The company has a quick ratio of 32.11, a current ratio of 32.11 and a debt-to-equity ratio of 0.03. QuantumScape has a twelve month low of $8.22 and a twelve month high of $43.08.
QuantumScape (NYSE:QS – Get Rating) last issued its quarterly earnings data on Wednesday, July 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). During the same period in the prior year, the company posted ($0.44) earnings per share. The company’s quarterly revenue was up NaN% on a year-over-year basis. On average, analysts predict that QuantumScape will post -0.9 EPS for the current year.
Analyst Ratings Changes
Insider Transactions at QuantumScape
In other news, CFO Kevin Hettrich sold 46,285 shares of the firm’s stock in a transaction on Monday, September 12th. The stock was sold at an average price of $11.18, for a total value of $517,466.30. Following the transaction, the chief financial officer now directly owns 400,225 shares in the company, valued at approximately $4,474,515.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other QuantumScape news, Director Fritz Prinz sold 270,301 shares of QuantumScape stock in a transaction dated Monday, August 15th. The stock was sold at an average price of $13.30, for a total transaction of $3,595,003.30. Following the transaction, the director now directly owns 267,482 shares in the company, valued at $3,557,510.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Kevin Hettrich sold 46,285 shares of QuantumScape stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $11.18, for a total value of $517,466.30. Following the transaction, the chief financial officer now owns 400,225 shares in the company, valued at $4,474,515.50. The disclosure for this sale can be found here. Insiders have sold 1,139,096 shares of company stock worth $13,751,433 in the last three months. Insiders own 13.73% of the company’s stock.
Institutional Investors Weigh In On QuantumScape
A number of institutional investors have recently made changes to their positions in the company. Atticus Wealth Management LLC bought a new stake in shares of QuantumScape in the first quarter valued at approximately $27,000. Fifth Third Bancorp boosted its stake in shares of QuantumScape by 103.6% in the first quarter. Fifth Third Bancorp now owns 1,425 shares of the company’s stock valued at $28,000 after buying an additional 725 shares during the period. Nauset Wealth Management. LLC bought a new stake in shares of QuantumScape in the first quarter valued at approximately $30,000. Investors Asset Management of Georgia Inc. GA ADV bought a new stake in shares of QuantumScape in the second quarter valued at approximately $30,000. Finally, Confluence Wealth Services Inc. bought a new stake in QuantumScape during the fourth quarter worth $32,000. Institutional investors own 25.44% of the company’s stock.
QuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
- Get a free copy of the StockNews.com research report on QuantumScape (QS)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
Receive News & Ratings for QuantumScape Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuantumScape and related companies with MarketBeat.com's FREE daily email newsletter.